Last reviewed · How we verify
Experimental: LAS 41004 dosage 3 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Experimental: LAS 41004 dosage 3 (Experimental: LAS 41004 dosage 3) — Almirall, S.A..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Experimental: LAS 41004 dosage 3 TARGET | Experimental: LAS 41004 dosage 3 | Almirall, S.A. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Experimental: LAS 41004 dosage 3 CI watch — RSS
- Experimental: LAS 41004 dosage 3 CI watch — Atom
- Experimental: LAS 41004 dosage 3 CI watch — JSON
- Experimental: LAS 41004 dosage 3 alone — RSS
Cite this brief
Drug Landscape (2026). Experimental: LAS 41004 dosage 3 — Competitive Intelligence Brief. https://druglandscape.com/ci/experimental-las-41004-dosage-3. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab